Molecular analysis of a patient with type i Glanzmann thrombasthenia and clinical impact of the presence of anti-αIIbβ3 alloantibodies

International Journal of Hematology

Volumn 93, Issue 1, 2011, Pages 106-111

  Kashiwagi, Hirokazu ^a   Kiyomizu, Kazunobu ^a   Kamae, Tsuyoshi ^a   Nakazawa, Tsuyoshi ^a   Tadokoro, Seiji ^a   Takiguchi, Shuji ^a   Doki, Yuichiro ^a   Kanakura, Yuzuru ^a   Tomiyama, Yoshiaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti IIb 3 alloantibody; Glanzmann thrombasthenia; Mutation; Platelet transfusion; Recombinant factor VIIa

Indexed keywords

ALLOANTIBODY; ARGININE; COMPLEMENTARY DNA; DISEASE CLASS; HLA ANTIBODY; IMMUNOGLOBULIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHAIIBBETA3; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ADULT; APHERESIS; ARTICLE; BLEEDING; CASE REPORT; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; EXON; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC CODE; GLANZMANN DISEASE; HLA SYSTEM; HOMOZYGOSITY; HUMAN; LAPAROSCOPIC SURGERY; MALE; NONSENSE MUTATION; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH CANCER; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ASIAN CONTINENTAL ANCESTRY GROUP; CODON, NONSENSE; HUMANS; INTEGRIN BETA3; ISOANTIBODIES; JAPAN; MALE; MIDDLE AGED; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBASTHENIA;

EID: 78751569929     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0731-5     Document Type: Article

References (16)

1. Y Tomiyama 2000 Glanzmann thrombasthenia: integrin αIIbβ3 deficiency Int J Hematol 72 448 454 1:CAS:528:DC%2BD3MXntVSjtw%3D%3D 11197210
2. Y Gruel E Brojer DJ Nugent TJ Kunicki 1994 Further characterization of the thrombasthenia-related idiotype OG. Antiidiotype defines a novel epitope(s) shared by fibrinogen B beta chain, vitronectin, and von Willebrand factor and required for binding to β3 J Exp Med 180 2259 2267 1:CAS:528: DyaK2cXmsFemsrc%3D 10.1084/jem.180.6.2259 7525851
3. K Ito H Yoshida H Hatoyama H Matsumoto C Ban T Mori, et al. 1991 Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies Vox Sang 61 40 46 1:STN:280:DyaK38%2Fls1KntQ%3D%3D 10.1111/j.1423-0410.1991.tb00925.x 1949709
4. I Martin F Kriaa V Proulle B Guillet C Kaplan R D'Oiron, et al. 2002 Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies Br J Haematol 119 991 997 1:CAS:528:DC%2BD3sXnt12msA%3D%3D 10.1046/j.1365-2141.2002.03936.x 12472579
5. L Tengborn B Petruson 1996 A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa Thromb Hemost 75 981 982 1:CAS:528:DyaK28XktVOksL8%3D
6. MC Poon R D'Oiron M Von Depka K Khair C Négrier A Karafoulidou, et al. 2004 International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey J Thromb Haemost 2 1096 1103 1:CAS:528:DC%2BD2cXmtl2ku78%3D 10.1111/j.1538-7836.2004.00767.x 15219192
7. S Kosugi Y Tomiyama S Honda H Kato T Kiyoi H Kashiwagi, et al. 2001 Platelet-associated anti-GPIIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura recognizing epitopes close to the ligand-binding site of glycoprotein (GP) IIb Blood 98 1819 1827 1:CAS:528:DC%2BD3MXntFWgtro%3D 10.1182/blood.V98.6.1819 11535516
8. S Bellucci J Caen 2002 Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment Blood Rev 16 193 202 1:STN:280: DC%2BD38vgvVyrug%3D%3D 10.1016/S0268-960X(02)00030-9 12163005
9. C Santoro A Rago F Biondo L Conti F Pulcinelli L Laurenti, et al. 2010 Prevalence of allo-immunization anti-HLA and anti-integrin αIIbβ3 in Glanzmann Thrombasthenia patients Haemophilia 16 805 812 1:CAS:528: DC%2BC3cXht12msbjJ 10.1111/j.1365-2516.2010.02230.x 20345392
10. C Male D Koren B Eichelberger K Kaufmann S Panzer 2006 Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thrombelastography Vox Sang 91 174 177 1:STN:280: DC%2BD28vosFertg%3D%3D 10.1111/j.1423-0410.2006.00797.x 16907879
11. Y Dargaud JC Bordet MC Trzeciak C Vinciguerra C Negrier 2006 A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observation on the monitoring and the mechanism of this drug Haemotologica 91 58 61
12. AT Nurden T Kunicki P Nurden M Fiore N Martins R Heilig, et al. 2010 Mutation analysis for a patient with Glanzmann Thrombasthenia who produced a landmark alloantibody to the αIIbβ3 integrin J Thromb Haemost 8 1866 1868 1:CAS:528:DC%2BC3cXhtFKkur3K 10.1111/j.1538-7836.2010.03920.x 20492470
13. A Nurden R Combrie P Nurden 2002 Detection of transfused platelets in a patient with Glanzmann thrombasthenia Thromb Haemost 87 543 544 1:CAS:528:DC%2BD38XislGjs7Y%3D 11916093
14. SJ Shattil M Cunningham JA Hoxie 1987 Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry Blood 70 307 315 1:STN:280:DyaL2s3kt12ntg%3D%3D 3297204
15. DM Monroe M Hoffman JA Oliver HR Roberts 1997 Platelet activity of high-dose factor VIIa is independent of tissue factor Br J Haematol 99 542 547 1:CAS:528:DyaK2sXnvF2mu70%3D 10.1046/j.1365-2141.1997.4463256.x 9401063
16. MC Poon 2007 Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia Vasc Health Risk Manag 3 655 1:CAS:528: DC%2BD2sXhsVelurfL 18078017